INS and diabetes mellitus: Interestingly, the CLVer trial with its factorial design of participants receiving either intensive diabetes management with an automated insulin delivery system or standard diabetes care in addition to verapamil or placebo, nicely demonstrated that while advanced technology can yield optimal glucose control, this is not sufficient to impact beta cell pathology or delay disease progression (40) underlining the need for better pharmacological interventions.